TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26827074

Group type: EXPERIMENTAL
Intervention: Fingolimod 0.5 mg/day
Number of subjects: 970

Group type: EXPERIMENTAL
Intervention: Fingolimod 1.25 mg/day
Number of subjects: 970

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 970
Study: 24506809

Group type: EXPERIMENTAL
Intervention: Inorganic sunscreen (SPF 50)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Foundation (SPF 50)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Light-blocking plaster
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (unprotected)
Number of subjects: 15
Study: 21067832

Group type: EXPERIMENTAL
Intervention: L-citrulline 5.6g/day for 7 days
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 20226331

Group type: EXPERIMENTAL
Intervention: Tigecycline
Number of subjects: 844
Study: 16821119

Group type: EXPERIMENTAL
Intervention: ICE-guided transcatheter closure
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control (non-ICE-guided transcatheter closure)
Number of subjects: 25
Study: 16222060

Group type: EXPERIMENTAL
Intervention: Octreotide (100 mug subcutaneously)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 14589718

Group type: EXPERIMENTAL
Intervention: Normal Conditions (NC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Faking Bad (FB)
Number of subjects: 0
Study: 9878017

Group type: EXPERIMENTAL
Intervention: Triple-drug therapy
Number of subjects: 12

Group type: COMPARATOR
Intervention: Drug-containing arms of the cultures
Number of subjects: 12
Study: 8573357

Group type: EXPERIMENTAL
Intervention: PMR visits (experimental group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no training or special treatment)
Number of subjects: 40
Study: 1957129

Group type: EXPERIMENTAL
Intervention: Cefixime (8 mg/kg/day for 7 days)
Number of subjects: 397

Group type: COMPARATOR
Intervention: Cefaclor (40 mg/kg/day for 7 days)
Number of subjects: 397

Group type: EXPERIMENTAL
Intervention: Cefixime
Number of subjects: 397

Group type: COMPARATOR
Intervention: Cefaclor
Number of subjects: 397
Study: 7044529

Group type: COMPARATOR
Intervention: Tamoxifen (TAM) alone
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Tamoxifen plus aminoglutethimide (TAM plus AG)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Aminoglutethimide (AG) in patients with prior tamoxifen exposure
Number of subjects: 91
Study: 30497085

Group type: EXPERIMENTAL
Intervention: Perceval sutureless bioprosthesis
Number of subjects: 1234

Group type: COMPARATOR
Intervention: Standard sutured stented bioprosthetic aortic valve
Number of subjects: 1234
Study: 31639022

Group type: EXPERIMENTAL
Intervention: Postoperative patients
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Postoperative feedback
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Elderly patients
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Males
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Unmarried individuals
Number of subjects: 85

Group type: COMPARATOR
Intervention: Different levels of education
Number of subjects: 85
Study: 28391880

Group type: EXPERIMENTAL
Intervention: Kefir drink
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Low-fat milk
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (weight-maintenance diet with 2 servings/d of low-fat dairy products)
Number of subjects: 75
Study: 27515877

Group type: EXPERIMENTAL
Intervention: Sage tea-thyme-peppermint hydrosol oral rinse
Number of subjects: 60

Group type: COMPARATOR
Intervention: Basic oral care (Control)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups (Intervention and Control)
Number of subjects: 60
Study: 24958796

Group type: EXPERIMENTAL
Intervention: Nasal carriage of Staphylococcus aureus
Number of subjects: 928

Group type: EXPERIMENTAL
Intervention: Hand carriage of Staphylococcus aureus
Number of subjects: 928

Group type: EXPERIMENTAL
Intervention: MRSA nasal carriers
Number of subjects: 928

Group type: EXPERIMENTAL
Intervention: Hand MRSA carriage without nasal S. aureus carriage
Number of subjects: 928

Group type: COMPARATOR
Intervention: Duration of jail stay
Number of subjects: 928
Study: 21153759

Group type: EXPERIMENTAL
Intervention: Just for You (JFY) Program
Number of subjects: 679

Group type: COMPARATOR
Intervention: Usual WIC Care
Number of subjects: 679
Study: 20408942

Group type: EXPERIMENTAL
Intervention: Sleep Restriction (4-h sleep for 5 days)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (8-h sleep each night)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Recovery (8-h sleep for 2 days after SR)
Number of subjects: 20
Study: 17903056

Group type: EXPERIMENTAL
Intervention: Hemorrhoidectomy with sphincterotomy (Group A)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Hemorrhoidectomy alone (Group B)
Number of subjects: 120
Study: 15722783

Group type: EXPERIMENTAL
Intervention: Opioids for chronic nonmalignant pain management
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 12236852

Group type: EXPERIMENTAL
Intervention: Ezetimibe 0.25 mg, 1 mg, or 10 mg with Simvastatin 10 mg
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg with Simvastatin 10 mg or 20 mg
Number of subjects: 82

Group type: COMPARATOR
Intervention: Simvastatin 10 mg alone
Number of subjects: 82

Group type: COMPARATOR
Intervention: Simvastatin 20 mg alone
Number of subjects: 82
Study: 9929524

Group type: EXPERIMENTAL
Intervention: Coumarin (200 mg orally, twice daily for six months)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo (twice daily for six months)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Coumarin
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study: 7567754

Group type: EXPERIMENTAL
Intervention: Polyethylene glycol/balanced electrolyte (PEG) mixture
Number of subjects: 89

Group type: COMPARATOR
Intervention: Mannitol/Picolax mixture
Number of subjects: 89
Study: 2246608

Group type: EXPERIMENTAL
Intervention: Fish oil diet (10-17 g of n-3 FAs per day)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control diet (cocoa butter and peanut oil)
Number of subjects: 10
Study: 6286274

Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 258

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 258
Study: 30975738

Group type: EXPERIMENTAL
Intervention: Direct aspiration (ADAPT)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Stent retriever
Number of subjects: 300
Study: 27879460

Group type: EXPERIMENTAL
Intervention: Glucantime therapy for 1 week after defervescence
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: Glucantime therapy for 7 days after defervescence
Number of subjects: 392

Group type: COMPARATOR
Intervention: WHO's regimen (28 days)
Number of subjects: 392
Study: 26472263

Group type: EXPERIMENTAL
Intervention: Selective head cooling (SHC)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Whole body cooling (WBC)
Number of subjects: 40
Study: 23672977

Group type: EXPERIMENTAL
Intervention: Single priming dose of NeisVac-C® vaccine at 4 or 6 months of age
Number of subjects: 0

Group type: COMPARATOR
Intervention: Two dose priming vaccination at 2 and 4 months of age
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single priming dose of NeisVac-C® vaccine at 4 months
Number of subjects: 0
Study: 21712645

Group type: EXPERIMENTAL
Intervention: qHPV vaccine
Number of subjects: 4065

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4065
Study: 19389021

Group type: EXPERIMENTAL
Intervention: RBCs of 7 +/- 4 days' storage duration
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: RBCs of 21 +/- 4 days' storage duration
Number of subjects: 43

Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 43
Study: 17535284

Group type: EXPERIMENTAL
Intervention: Slim-line scaler tip (Perio Pro Line Instrument SI-11)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional scaler tip (Instrument No. 3)
Number of subjects: 20
Study: 16418103

Group type: EXPERIMENTAL
Intervention: New functional-sexological treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Behavioral treatment (squeeze and stop-and-start techniques)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (waiting list)
Number of subjects: 0
Study: 15374846

Group type: EXPERIMENTAL
Intervention: Inhaled triamcinolone acetonide, 600 mcg, twice daily
Number of subjects: 412

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 412
Study: 10714845

Group type: EXPERIMENTAL
Intervention: Propofol (induction with 3 mg x kg(‐1), maintenance with 100-250 microg x kg(‐1) min(‐1))
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sevoflurane (induction 7 vol.%, maintenance 2-3 vol.%)
Number of subjects: 50
Study: 8942332

Group type: EXPERIMENTAL
Intervention: 20% Human Albumin (HA)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: 10% Low-molecular weight Hydroxyethylstarch (HES)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Vasopressors (vasopressin, endothelin-1, noradrenaline, adrenaline)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Mean arterial pressure (MAP), heart rate (HR), pulmonary capillary wedge pressure (PCWP)
Number of subjects: 56
Study: 1410230

Group type: EXPERIMENTAL
Intervention: skills-building group
Number of subjects: 91

Group type: COMPARATOR
Intervention: information-only group
Number of subjects: 91
Study: 4016930

Group type: EXPERIMENTAL
Intervention: Flunarizine, 10 mg a day for up to 120 days
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 31551029

Group type: EXPERIMENTAL
Intervention: Rapamycin (RAPA)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Rapamycin (RAPA) + all-trans retinoic acid (ATRA)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (RAPA vs RAPA + ATRA)
Number of subjects: 70
Study: 28679946

Group type: EXPERIMENTAL
Intervention: Dietary weight loss intervention
Number of subjects: 52

Group type: COMPARATOR
Intervention: Habitual diet
Number of subjects: 52
Study: 26061132

Group type: EXPERIMENTAL
Intervention: Endoscopic thyroidectomy via oral vestibular approach (ETOVA)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Endoscopic thyroidectomy via areola approach (ETAA)
Number of subjects: 82
Study: 23137700

Group type: EXPERIMENTAL
Intervention: bilateral continuous theta burst stimulation to the temporal cortex
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: bilateral continuous theta burst stimulation to the temporoparietal cortex
Number of subjects: 48

Group type: COMPARATOR
Intervention: non-cortical control site
Number of subjects: 48
Study: 21704944

Group type: EXPERIMENTAL
Intervention: Burr-hole irrigation with drainage (BI+D)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Burr-hole irrigation without drainage (BI-D)
Number of subjects: 40
Study: 19487235

Group type: COMPARATOR
Intervention: Bridging from oral anticoagulation (OAC) to intravenous heparin infusion (n = 51)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Maintenance of oral anticoagulation (OAC) to reach an INR = 2 +/- 0.3 (n = 50)
Number of subjects: 101
Study: 17590310

Group type: EXPERIMENTAL
Intervention: Adaptation period present with observation
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Adaptation period absent with observation
Number of subjects: 80

Group type: COMPARATOR
Intervention: Adaptation period absent without observation
Number of subjects: 80
Study: 15172900

Group type: EXPERIMENTAL
Intervention: Fondaparinux, 7.5 mg (5.0 mg in patients weighing <50 kg and 10.0 mg in patients weighing >100 kg) subcutaneously once daily
Number of subjects: 2205

Group type: COMPARATOR
Intervention: Enoxaparin, 1 mg/kg of body weight, subcutaneously twice daily
Number of subjects: 2205

Group type: EXPERIMENTAL
Intervention: Fondaparinux
Number of subjects: 2205

Group type: COMPARATOR
Intervention: Enoxaparin
Number of subjects: 2205
Study: 11250761

Group type: EXPERIMENTAL
Intervention: Finasteride cream (0.25%)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 8
Study: 9054247

Group type: EXPERIMENTAL
Intervention: Lumbar sympathetic nerve block with 10 ml bupivacaine (0.5%)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Contralateral placebo block with 10 ml saline
Number of subjects: 16
Study: 7931867

Group type: EXPERIMENTAL
Intervention: Enhanced methadone maintenance group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard methadone maintenance group
Number of subjects: 0
Study: 3322956

Group type: EXPERIMENTAL
Intervention: Ispaghula husk
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Ispaghula husk and Placebo
Number of subjects: 80
Study: 29601570

Group type: EXPERIMENTAL
Intervention: MCH-ART intervention
Number of subjects: 471

Group type: COMPARATOR
Intervention: Control (standard care)
Number of subjects: 471
Study: 28780543

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Sham electroacupuncture (SEA)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Routine postoperative pain control (Control group)
Number of subjects: 138
Study: 26917025

Group type: EXPERIMENTAL
Intervention: Screw proximal femoral nail (PFN)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Helical proximal femoral nail (PFN)
Number of subjects: 77
Study: 22415358

Group type: EXPERIMENTAL
Intervention: 4-Meter Walk Test
Number of subjects: 43

Group type: COMPARATOR
Intervention: 10-Meter Walk Test
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Stopwatch timing method
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Automatic timer timing method
Number of subjects: 43
Study: 22031660

Group type: EXPERIMENTAL
Intervention: High-beef diet with low-saturated fat (8% E)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: High-beef diet with high-saturated fat (15% E)
Number of subjects: 40
Study: 18835965

Group type: EXPERIMENTAL
Intervention: Cisatracurium 0.15 mg x kg(‐1) i.v.
Number of subjects: 130

Group type: COMPARATOR
Intervention: Saline (Placebo)
Number of subjects: 130
Study: 16534653

Group type: EXPERIMENTAL
Intervention: Intraarterial chemotherapy (IARC) after potentially curative gastrectomy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Gastrectomy only (control group)
Number of subjects: 40
Study: 15562178

Group type: EXPERIMENTAL
Intervention: Multijoint dynamic resistance training (MJDR group)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Dumbbell exercises (isolated group)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Isokinetic strengthening programme (isokinetic group)
Number of subjects: 48

Group type: COMPARATOR
Intervention: No strength training (control group)
Number of subjects: 48
Study: 10686463

Group type: EXPERIMENTAL
Intervention: ferrous sulfate 325 mg b.i.d.
Number of subjects: 28

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 28
Study: 9189056

Group type: EXPERIMENTAL
Intervention: Local steroid injection (15 mg of triamcinolone hexacetonide and 1 ml of 2% lidocaine)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Ultrasonographic examination
Number of subjects: 9
Study: 1552198

Group type: EXPERIMENTAL
Intervention: anti-J5 plasma
Number of subjects: 73

Group type: COMPARATOR
Intervention: control plasma
Number of subjects: 73
Study: 3862158

Group type: EXPERIMENTAL
Intervention: Intensive social skills training
Number of subjects: 28

Group type: COMPARATOR
Intervention: Holistic health therapy
Number of subjects: 28
Study: 30015736

Group type: EXPERIMENTAL
Intervention: Diode laser
Number of subjects: 21

Group type: COMPARATOR
Intervention: Cold blade
Number of subjects: 21
Study: 26546248

Group type: EXPERIMENTAL
Intervention: C-Reactive Protein (CRP) levels >2 mg/L
Number of subjects: 16
Study: 24112375

Group type: EXPERIMENTAL
Intervention: Diet+IDet (Insulin detemir with dietary intervention)
Number of subjects: 100

Group type: COMPARATOR
Intervention: IDet (Insulin detemir alone)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study: 24188082

Group type: EXPERIMENTAL
Intervention: Multisystemic Therapy (MST)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 124
Study: 20602168

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 142

Group type: COMPARATOR
Intervention: Sodium bicarbonate
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 142
Study: 17575560

Group type: EXPERIMENTAL
Intervention: Communication Skills Training (CST)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (no CST)
Number of subjects: 30
Study: 17243612

Group type: EXPERIMENTAL
Intervention: Combination of amlodipine and verapamil retard
Number of subjects: 43
Study: 14671204

Group type: EXPERIMENTAL
Intervention: 1 mg dexamethasone twice daily for 6 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11192708

Group type: EXPERIMENTAL
Intervention: 30 ml of castor oil the night before imaging (Group B)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Bisacodyl the night before imaging (Group C)
Number of subjects: 150

Group type: COMPARATOR
Intervention: No bowel preparation (Group A)
Number of subjects: 150
Study: 9017787

Group type: EXPERIMENTAL
Intervention: Allergen bronchoprovocation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Drugs effective as maintenance therapy (e.g., inhaled corticosteroids)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ineffective drugs (e.g., calcium channel blockers, ketotifen, antihistamines)
Number of subjects: 0
Study: 8435990

Group type: EXPERIMENTAL
Intervention: Ethanol 0.5 g kg‐1 by intravenous bolus followed by 0.25 g kg‐1 h‐1
Number of subjects: 9

Group type: COMPARATOR
Intervention: Matched volumes of saline
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Ethanol
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 9
Study: 3462013

Group type: EXPERIMENTAL
Intervention: Cladosporium herbarum inhalation (concentrations: 1:100000, 1:10000, 1:1000, 1:100)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Histamine inhalation (concentrations: 0.3, 0.6, 1.2, 2.4 mg/ml)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Saline inhalation
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Cladosporium herbarum inhalation
Number of subjects: 5
Study: 29764270

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of ethanol (blood alcohol level=80 mg%)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 26952945

Group type: EXPERIMENTAL
Intervention: Fosaprepitant 150 mg intravenously in combination with palonosetron 0.25 mg intravenously and dexamethasone 16 mg orally.
Number of subjects: 234

Group type: COMPARATOR
Intervention: Placebo (saline) in combination with palonosetron 0.25 mg intravenously and dexamethasone 16 mg orally.
Number of subjects: 234
Study: 24353113

Group type: EXPERIMENTAL
Intervention: 2-day group (bile sampled five times per day for 2 days)
Number of subjects: 100

Group type: COMPARATOR
Intervention: 10-day group (bile sampled once per day for 10 days)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 2-day group
Number of subjects: 100

Group type: COMPARATOR
Intervention: 10-day group
Number of subjects: 100
Study: 23866410

Group type: COMPARATOR
Intervention: On-demand tadalafil (10mg)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Once-daily tadalafil (10mg)
Number of subjects: 100
Study: 20831016

Group type: EXPERIMENTAL
Intervention: Thiaprofenic acid
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Meloxicam
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Piroxicam
Number of subjects: 240
Study: 18088349

Group type: EXPERIMENTAL
Intervention: TTP889 (300 mg once daily)
Number of subjects: 261

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 261
Study: 15988284

Group type: EXPERIMENTAL
Intervention: Active warming during surgery with countercurrent fluid warming and forced-air skin warming
Number of subjects: 76

Group type: COMPARATOR
Intervention: Standard sterile drapes (control group)
Number of subjects: 76
Study: 12490512

Group type: EXPERIMENTAL
Intervention: Routine evaluation of deep calf veins
Number of subjects: 496

Group type: COMPARATOR
Intervention: Selective evaluation of calf veins (only if symptoms or signs present)
Number of subjects: 496
Study: 12449522

Group type: EXPERIMENTAL
Intervention: Granisetron (3 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Granisetron plus droperidol (3 mg granisetron and 1.25 mg droperidol)
Number of subjects: 60
Study: 9887116

Group type: EXPERIMENTAL
Intervention: Flavored water plus 6% carbohydrate and 18 mmol/l Na (CNa)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Unflavored water (W)
Number of subjects: 12
Study: 8770842

Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 0
Study: 2039639

Group type: EXPERIMENTAL
Intervention: Continuous alfentanil infusion (100 micrograms/kg bolus followed by continuous infusion)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Halothane and nitrous oxide (N2O)
Number of subjects: 40
Study: 7469185

Group type: EXPERIMENTAL
Intervention: Drained group
Number of subjects: 76

Group type: COMPARATOR
Intervention: Nondrained group
Number of subjects: 76
Study: 6696838

Group type: EXPERIMENTAL
Intervention: PUVA-etretinate (1 mg/kg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: PUVA-placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: PUVA-etretinate
Number of subjects: 20
Study: 29382509

Group type: EXPERIMENTAL
Intervention: Active Tube Clearance (ATC)
Number of subjects: 581

Group type: COMPARATOR
Intervention: Control (conventional chest tubes)
Number of subjects: 581
Study: 27965296

Group type: EXPERIMENTAL
Intervention: Deferred Stenting (DS)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Immediate Stenting (IS)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Deferred Stenting (DS) in anterior wall myocardial infarction
Number of subjects: 114

Group type: COMPARATOR
Intervention: Immediate Stenting (IS) in anterior wall myocardial infarction
Number of subjects: 114
Study: 24535759

Group type: EXPERIMENTAL
Intervention: Cryolipolysis treatment on the flank
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control (untreated flank)
Number of subjects: 11
Study: 23769296

Group type: EXPERIMENTAL
Intervention: 45 mg ustekinumab
Number of subjects: 615

Group type: EXPERIMENTAL
Intervention: 90 mg ustekinumab
Number of subjects: 615

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 615

Group type: EXPERIMENTAL
Intervention: Ustekinumab (both doses)
Number of subjects: 615